Mitochondrial Metabolism As a Target for Cancer Therapy

Overview

Journal Cell Metab

Publisher Cell Press

Specialties Cell Biology
Endocrinology

Date 2020 Jul 16

PMID 32668195

Citations 273

Authors

Karthik Vasan

Marie Werner

Navdeep S Chandel

Affiliations

Soon will be listed here.

Abstract

Recent evidence in humans and mice supports the notion that mitochondrial metabolism is active and necessary for tumor growth. Mitochondrial metabolism supports tumor anabolism by providing key metabolites for macromolecule synthesis and generating oncometabolites to maintain the cancer phenotype. Moreover, there are multiple clinical trials testing the efficacy of inhibiting mitochondrial metabolism as a new cancer therapeutic treatment. In this review, we discuss the rationale of using these anti-cancer agents in clinical trials and highlight how to effectively utilize them in different tumor contexts.

Citing Articles

SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.

Yu H, Bai L, Jin L, Zhang Y, Xi Z, Wang D Cell Commun Signal. 2025; 23(1):130.

PMID: 40065301 PMC: 11895242. DOI: 10.1186/s12964-025-02109-y.

Renal-clearable and tumor-retained nanodots overcoming metabolic reprogramming to boost mitochondrial-targeted photodynamic therapy in triple-negative breast cancer.

Yao D, Wang Y, Dong X, Chen Y, Ji D, Zou R J Nanobiotechnology. 2025; 23(1):195.

PMID: 40059207 PMC: 11892270. DOI: 10.1186/s12951-025-03264-7.

AC129507.1 is a ferroptosis-related target identified by a novel mitochondria-related lncRNA signature that is involved in the tumor immune microenvironment in gastric cancer.

Yu S, Liang J, Liu L, Chen M, Chen C, Zhou D J Transl Med. 2025; 23(1):290.

PMID: 40050892 PMC: 11887229. DOI: 10.1186/s12967-025-06287-8.

A Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer.

Bian K, Yang C, Zhang F, Huang L Int J Mol Sci. 2025; 26(4).

PMID: 40004017 PMC: 11855622. DOI: 10.3390/ijms26041551.

Unlocking the future: mitochondrial genes and neural networks in predicting ovarian cancer prognosis and immunotherapy response.

Tang Z, Pan Y, Li W, Ma R, Wang J Transl Cancer Res. 2025; 14(1):512-521.

PMID: 39974375 PMC: 11833377. DOI: 10.21037/tcr-24-1233.

References

Zdralevic M, Brand A, Di Ianni L, Dettmer K, Reinders J, Singer K . Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolism. J Biol Chem. 2018; 293(41):15947-15961. PMC: 6187639. DOI: 10.1074/jbc.RA118.004180. View

Siegelin M, Dohi T, Raskett C, Orlowski G, Powers C, Gilbert C . Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011; 121(4):1349-60. PMC: 3069780. DOI: 10.1172/JCI44855. View

Hirsch H, Iliopoulos D, Tsichlis P, Struhl K . Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69(19):7507-11. PMC: 2756324. DOI: 10.1158/0008-5472.CAN-09-2994. View

Bajzikova M, Kovarova J, Coelho A, Boukalova S, Oh S, Rohlenova K . Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. Cell Metab. 2018; 29(2):399-416.e10. PMC: 7484595. DOI: 10.1016/j.cmet.2018.10.014. View

Hahn A, Parey K, Bublitz M, Mills D, Zickermann V, Vonck J . Structure of a Complete ATP Synthase Dimer Reveals the Molecular Basis of Inner Mitochondrial Membrane Morphology. Mol Cell. 2016; 63(3):445-56. PMC: 4980432. DOI: 10.1016/j.molcel.2016.05.037. View

Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z . Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20(5):674-88. PMC: 3221282. DOI: 10.1016/j.ccr.2011.10.015. View

Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sanchez N, Marchesini M . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514(7524):628-32. PMC: 4376130. DOI: 10.1038/nature13611. View

Cardaci S, Zheng L, Mackay G, van den Broek N, MacKenzie E, Nixon C . Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol. 2015; 17(10):1317-26. PMC: 4591470. DOI: 10.1038/ncb3233. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

10.

Rawls J, Knecht W, Diekert K, Lill R, Loffler M . Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase. Eur J Biochem. 2000; 267(7):2079-87. DOI: 10.1046/j.1432-1327.2000.01213.x. View

11.

Bailis W, Shyer J, Zhao J, Garcia Canaveras J, Al Khazal F, Qu R . Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. Nature. 2019; 571(7765):403-407. PMC: 6939459. DOI: 10.1038/s41586-019-1311-3. View

12.

Zong W, Rabinowitz J, White E . Mitochondria and Cancer. Mol Cell. 2016; 61(5):667-676. PMC: 4779192. DOI: 10.1016/j.molcel.2016.02.011. View

13.

Joshi S, Tolkunov D, Aviv H, Hakimi A, Yao M, Hsieh J . The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep. 2015; 13(9):1895-908. PMC: 4779191. DOI: 10.1016/j.celrep.2015.10.059. View

14.

Romero R, Sayin V, Davidson S, Bauer M, Singh S, LeBoeuf S . Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017; 23(11):1362-1368. PMC: 5677540. DOI: 10.1038/nm.4407. View

15.

Fu Z, Ye J, Dean J, Bostick J, Weinberg S, Xiong L . Requirement of Mitochondrial Transcription Factor A in Tissue-Resident Regulatory T Cell Maintenance and Function. Cell Rep. 2019; 28(1):159-171.e4. PMC: 6679941. DOI: 10.1016/j.celrep.2019.06.024. View

16.

Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M . Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2010; 30(10):1174-82. DOI: 10.1038/onc.2010.483. View

17.

Nowicki S, Gottlieb E . Oncometabolites: tailoring our genes. FEBS J. 2015; 282(15):2796-805. PMC: 4676302. DOI: 10.1111/febs.13295. View

18.

Arrieta O, Barron F, Padilla M, Aviles-Salas A, Ramirez-Tirado L, Arguelles Jimenez M . Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(11):e192553. PMC: 6735425. DOI: 10.1001/jamaoncol.2019.2553. View

19.

Brown J, Chan D, Shank J, Griffith K, Fan H, Szulawski R . Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020; 5(11). PMC: 7308054. DOI: 10.1172/jci.insight.133247. View

20.

Oshima N, Ishida R, Kishimoto S, Beebe K, Brender J, Yamamoto K . Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy. Cell Rep. 2020; 30(6):1798-1810.e4. PMC: 7039685. DOI: 10.1016/j.celrep.2020.01.039. View